{
  "nctId": "NCT03501550",
  "briefTitle": "Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)",
  "officialTitle": "An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment With 2 Weeks of the Non-Nucleoside Inhibitor CDI 31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects With Chronic Hepatitis C Genotype 1 Infection",
  "protocolDocument": {
    "nctId": "NCT03501550",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2018-05-22",
    "uploadDate": "2021-03-31T20:40",
    "size": 9607675,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03501550/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 12,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-06-26",
    "completionDate": "2019-06-07",
    "primaryCompletionDate": "2019-01-08",
    "firstSubmitDate": "2018-04-09",
    "firstPostDate": "2018-04-18"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\nDocumented chronic HCV GT 1 infection; Serum HCV RNA \\>1,000 IU/mL during screening; Absence of advanced fibrosis or cirrhosis\n\nKey Exclusion Criteria:\n\nNursing or pregnant women; Active hepatitis B infection; Human immunodeficiency virus (HIV) infection; History of use of any HCV direct-acting antiviral therapy",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Subjects With Treatment Emergent Adverse Events",
        "description": "The safety and the tolerability of CDI-31244 in combination with SOF/VEL through number of AEs observed in participants",
        "timeFrame": "Day 1 to Day 72"
      },
      {
        "measure": "Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After Treatment",
        "description": "SVR12 is defined as HCV RNA \\< the lower limit of quantitation (LLOQ) at 12 weeks after treatment",
        "timeFrame": "post-treatment Week 12"
      }
    ],
    "secondary": [
      {
        "measure": "Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After Discontinuation of Therapy",
        "description": "SVR (sustained virologic response) 24 is defined as HCV RNA \\< the lower limit of quantitation (LLOQ) at 24 weeks after treatment",
        "timeFrame": "post-treatment Week 24"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:25.399Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}